Search results for "Highlights"


 
Results 91 - 100 of about 254 for "Highlights".

Socioeconomic status appears linked to mortality in patients with type 2 diabetes

The study looked at data from the Sweden National Diabetes Register to determine what patient characteristics were related to all-cause mortality or death from cardiovascular-, diabetes-, or cancer-related causes.
July 2016

Intensive glycemic treatment may be common, doubles risk of hypoglycemia

Intensive treatment was defined as use of more glucose-lowering medications than recommended by practice guidelines and was found in 18.7% of clinically complex Medicare patients.
June 2016

Thiazolidinedione add-ons associated with less CV risk, study finds

The U.K.-based retrospective cohort study used a database that linked national hospitalization and mortality data for people who were prescribed second-line regimens after metformin.
July 2016

Excess mortality examined in older patients with diabetes

Excess mortality associated with diabetes was highest in patients younger than age 75 who had had diabetes for a longer time period, with the relative hazard highest in women, a study found.
June 2016

1-hour glucose value may predict mortality risk

A 1-hour glucose value above 155 mg/dL predicted mortality even when the 2-hour glucose value was below 140 mg/dL, according to the 33-year study.
May 2016

Pioglitazone, but not rosiglitazone, associated with increased risk of bladder cancer

The results of this study pose the question of whether the increased likelihood of bladder cancer, which is rare, justifies withholding pioglitazone from adults with type 2 diabetes, according to an accompanying editorial.
April 2016

New risk score for CVD may be easier to use than existing scores in patients with diabetes

Researchers used data from the ADVANCE-ON study to develop the AD-ON risk score, a 10-year risk score for the combined endpoint of major cardiovascular disease (CVD) or chronic kidney disease.
February 2016

Incretin-based drugs not associated with greater heart failure hospitalization risk than other drug combos in retrospective study

Researchers compared patients taking dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues to those taking 2 or more oral antidiabetic drugs.
April 2016

FDA warns about ketoacidosis and urinary tract infections with SGLT2 inhibitors

The warnings are based on a review finding 73 cases of ketoacidosis in patients with type 1 or type 2 diabetes and 19 cases of life-threatening urosepsis and pyelonephritis.
December 2015

Combined canagliflozin, metformin may offer better glycemic control than monotherapy, study finds

The industry-funded, double-blind, randomized, controlled trial assigned adult patients with type 2 diabetes who were not taking antihyperglycemic agents before the study to 26 weeks of treatment in 1 of 5 arms.
February 2016

Result Page: Prev   5   6   7   8   9   10   11   12   13   14   Next